June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Slow-release intraocular drug delivery by injectable PEA microfibrils (DSM, NL)
Author Affiliations & Notes
  • Gabriele Thumann
    Department of Ophthalmology, University of Geneva, Geneva, Switzerland
  • George Mihov
    DSM, Geleen, Netherlands
  • Jens Thies
    DSM, Geleen, Netherlands
  • Anja Kemp
    DSM, Geleen, Netherlands
  • Katharina Morawa
    Department of Ophthalmology, University of Geneva, Geneva, Switzerland
  • Martina Kropp
    Department of Ophthalmology, University of Geneva, Geneva, Switzerland
  • Footnotes
    Commercial Relationships Gabriele Thumann, DSM (F); George Mihov, DSM (E); Jens Thies, None; Anja Kemp, DSM (E); Katharina Morawa, DSM Biomedical (F); Martina Kropp, DSM (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5045. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gabriele Thumann, George Mihov, Jens Thies, Anja Kemp, Katharina Morawa, Martina Kropp; Slow-release intraocular drug delivery by injectable PEA microfibrils (DSM, NL). Invest. Ophthalmol. Vis. Sci. 2013;54(15):5045.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Ophthalmic drug therapy of the posterior segment requires that effective concentrations of drug reach the target tissue, a goal complicated by limited penetration, short half-life of many drugs and difficult access to the posterior segment. Generally drug delivery to the posterior segment of the eye is accomplished by intravitreal (ivt) injection, often requiring frequent injections, e.g. AMD treatment with ranibizumab or aflibercept. Continuous drug delivery systems would be useful to avoid frequent administration and to deliver the drug at a more physiological concentration. Here we report properties of biodegradable amino acid polyester amide (PEA) polymers (DSM, NL) that can deliver a spectrum of drugs in a sustained, zero-order behavior and degrade via an enzyme-mediated pathway.

Methods: Deformability and in vitro degradation of the PEA fibrils (120-300 µm in diameter) was analyzed by incubation at 37o C in PBS, in α-chymotrypsin, in human, rabbit and bovine vitreous. In vivo biocompatibility and degradation was analyzed by subconjunctival (sc) and ivt implantation in normal and VEGF-treated rabbits that simulate blood-retinal barrier breakdown. Drug release by single PEA fibrils loaded with 10% dexamethasone was analyzed in vitro.

Results: During the first 2 hours the fibrils decreased in length 57% in PBS, 62% in rabbit vitreous and 59% in human vitreous; the decrease in length was accompanied by an increase in diameter. Degradation by chymotrypsin depended on the amino acid composition of the PEA. Degradation in normal vitreous was slight but increased in vitreous from VEGF-treated rabbits. Sc and ivt PEA fibrils were well tolerated with no evidence of inflammation, retinal damage or changes in IOP. After an initial peak dexamethasone was released at a constant rate of 0.05-1.0 µg/ml for 140 days, whereas PLGA 75/25 did not release significant amounts of dexamethasone during the first 120 days, followed by 90% release from day 120 to day 140.

Conclusions: PEA polymers (DSM, NL) are well tolerated in the ocular environment, degrade slowly intravitreally and can be loaded with drugs that are released with zero-order kinetics over a period of months. Since PEAs are well tolerated in the ocular environment and can be manufactured to be loaded with different classes of drugs, these materials would be ideal for sustained delivery of drugs to the posterior segment.

Keywords: 688 retina • 763 vitreous • 412 age-related macular degeneration  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.